NADPH-oxidase-dependent reactive oxygen species mediate EGFR transactivation by FPRL1 in WKYMVm-stimulated human lung cancer cells

Free Radic Biol Med. 2011 Sep 15;51(6):1126-36. doi: 10.1016/j.freeradbiomed.2011.05.040. Epub 2011 Jun 12.

Abstract

Cross talk between unrelated cell surface receptors, such as G-protein-coupled receptors (GPCR) and receptor tyrosine kinases (RTK), is a crucial signaling mechanism to expand the cellular communication network. We investigated the ability of the GPCR formyl peptide receptor-like 1 (FPRL1) to transactivate the RTK epidermal growth factor receptor (EGFR) in CaLu-6 cells. We observed that stimulation with WKYMVm, an FPRL1 agonist isolated by screening synthetic peptide libraries, induces EGFR tyrosine phosphorylation, p47(phox) phosphorylation, NADPH-oxidase-dependent superoxide generation, and c-Src kinase activity. As a result of EGFR transactivation, phosphotyrosine residues provide docking sites for recruitment and triggering of the STAT3 pathway. WKYMVm-induced EGFR transactivation is prevented by the FPRL1-selective antagonist WRWWWW, by pertussis toxin (PTX), and by the c-Src inhibitor PP2. The critical role of NADPH-oxidase-dependent superoxide generation in this cross-talk mechanism is corroborated by the finding that apocynin or a siRNA against p22(phox) prevents EGFR transactivation and c-Src kinase activity. In addition, WKYMVm promotes CaLu-6 cell growth, which is prevented by PTX and by WRWWWW. These results highlight the role of FPRL1 as a potential target of new drugs and suggest that targeting both FPRL1 and EGFR may yield superior therapeutic effects compared with targeting either receptor separately.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CSK Tyrosine-Protein Kinase
  • Cell Growth Processes / drug effects
  • Cell Line, Tumor
  • ErbB Receptors / metabolism*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Molecular Targeted Therapy
  • NADPH Oxidases / genetics
  • NADPH Oxidases / metabolism*
  • Oligopeptides / pharmacology
  • Phosphorylation
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / pharmacology
  • RNA, Small Interfering / genetics
  • Reactive Oxygen Species / metabolism
  • Receptor Cross-Talk
  • Receptors, Formyl Peptide / agonists
  • Receptors, Formyl Peptide / antagonists & inhibitors
  • Receptors, Formyl Peptide / metabolism*
  • Receptors, Lipoxin / agonists
  • Receptors, Lipoxin / antagonists & inhibitors
  • Receptors, Lipoxin / metabolism*
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction / drug effects
  • Transcriptional Activation / drug effects
  • src-Family Kinases

Substances

  • AG 1879
  • FPR2 protein, human
  • Oligopeptides
  • Pyrimidines
  • RNA, Small Interfering
  • Reactive Oxygen Species
  • Receptors, Formyl Peptide
  • Receptors, Lipoxin
  • STAT3 Transcription Factor
  • Trp-Lys-Tyr-Met-Val-Met
  • tryptophyl-arginyl-tryptophyl-tryptophyl-tryptophyl-tryptophanamide
  • NADPH Oxidases
  • CYBA protein, human
  • EGFR protein, human
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • CSK Tyrosine-Protein Kinase
  • src-Family Kinases
  • CSK protein, human